Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are ...

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

Chinese stocks ended higher, supported by home appliance and pharma stocks. Despite the impact of China's ...

Our Bureau, Mumbai Thursday, March 20, 2025, 09:00 Hrs [IST] CPHI & PMEC China, Asia's premier pharmaceutical event for sour ...

According to data from DealForma, as reported by CNBC, around 30% of Big Pharma deals with at least $50 million upfront in ...

They provide leverage that Trump should use to strike a deal with China to more comprehensively regulate its pharmaceutical ...

With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. | With the fate ...

Chinese firms can accelerate clinical trials and bring their drugs to market faster with more supportive policies, ...

According to data from DealForma, as reported by CNBC, around 30% of Big Pharma deals with at least $50 million upfront in 2024 included Chinese companies. This was up from 20% the year before and ...